Loading...
Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera(®) was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. Using the concept of PRRT, Lutathera(®) combine...
Na minha lista:
| Udgivet i: | Pharmaceuticals (Basel) |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6789871/ https://ncbi.nlm.nih.gov/pubmed/31362406 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph12030114 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|